Involvement of estrogen receptor-Β in farrerol inhibition of rat thoracic aorta vascular smooth muscle cell proliferation

Acta Pharmacologica Sinica

Volumn 32, Issue 4, 2011, Pages 433-440

  Li, Qun Yi ^a,b   Chen, Li ^a,c   Zhu, Yan Hui ^a   Zhang, Meng ^a   Wang, Yi Ping ^a   Wang, Ming Wei ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b FUDAN UNIVERSITY   (China)

^c TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

cell cycle; cell proliferation; ERK1 2; estrogen receptor; farrerol; phytoestrogen; receptor binding assay; vascular smooth muscle cells

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BROXURIDINE; CARDIOVASCULAR AGENT; CELL CYCLE PROTEIN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FARREROL; HERBACEOUS AGENT; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHYTOESTROGEN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING ASSAY; CELL ASSAY; CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHINESE HERB; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; DRUG EFFECT; DRUG RECEPTOR BINDING; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; IC 50; NONHUMAN; RAT; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; THORACIC AORTA; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ANIMALS; AORTA, THORACIC; BASE SEQUENCE; BLOTTING, WESTERN; CELL PROLIFERATION; CHROMONES; DNA PRIMERS; ESTROGEN RECEPTOR BETA; FLOW CYTOMETRY; MUSCLE, SMOOTH, VASCULAR; POLYMERASE CHAIN REACTION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 79953803498     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.1     Document Type: Article

References (34)

1. Rivard A, Andres V. Vascular smooth muscle cell proliferation in the pathogenesis of atherosclerotic cardiovascular diseases. Histol Histopathol 2000; 15: 557-71. (Pubitemid 30218852)
2. Andres V, Castro C. Antiproliferative strategies for the treatment of vascular proliferative disease. Curr Vasc Pharmacol 2003; 1: 85-98.
3. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453-61. (Pubitemid 26269944)
4. Dubey RK, Gillespie DG, Mi Z, Rosselli M, Keller PJ, Jackson EK. Estradiol inhibits smooth muscle cell growth in part by activating the cAMP-adenosine pathway. Hypertension 2000; 35: 262-6. (Pubitemid 30054183)
5. Akishita M, Ouchi Y, Miyoshi H, Kozaki K, Inoue S, Ishikawa M, et al. Estrogen inhibits cuff-induced intimal thickening of rat femoral artery: effects on migration and proliferation of vascular smooth muscle cells. Atherosclerosis 1997; 130: 1-10. (Pubitemid 27158023)
6. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33. (Pubitemid 34761611)
7. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-12. (Pubitemid 38489892)
8. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006; 166: 357-65. (Pubitemid 43244325)
9. Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hsia J, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007; 356: 2591-602. (Pubitemid 46961004)
10. Dubey RK, Gillespie DG, Imthurn B, Rosselli M, Jackson EK, Keller PJ. Phytoestrogens inhibit growth and MAP kinase activity in human aortic smooth muscle cells. Hypertension 1999; 33: 177-82. (Pubitemid 29065656)
11. Grainger DJ, Metcalfe JC. Tamoxifen: teaching an old drug new tricks? Nat Med 1996; 2: 381-5. (Pubitemid 26191903)
12. Cerquetani E, Vitale C, Mercuro G, Fini M, Zoncu S, Rosano GM. Comparative vascular effects of hormone replacement therapy and raloxifene in women at increased cardiovascular risk. Gynecol Endocrinol 2004; 18: 291-8. (Pubitemid 38916350)
13. Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 2006; 113: 1034-44. (Pubitemid 43879479)
14. Cassidy A, Hooper L. Phytoestrogens and cardiovascular disease. J Br Menopause Soc 2006; 12: 49-56. (Pubitemid 43881063)
15. Kim SY, Jin YR, Lim Y, Kim JH, Cho MR, Hong JT, et al. Inhibition of PDGFβ-receptor tyrosine phosphorylation and its downstream intracellular signal transduction in rat aortic vascular smooth muscle cells by kaempferol. Planta Med 2005; 71: 599-603. (Pubitemid 41133067)
16. Ibarra M, Perez-Vizcaino F, Cogolludo A, Duarte J, Zaragoza-Arnaez F, Lopez-Lopez JG, et al. Cardiovascular effects of isorhamnetin and quercetin in isolated rat and porcine vascular smooth muscle and isolated rat atria. Planta Med 2002; 68: 307-10. (Pubitemid 34494039)
17. Cao Y, Lou C, Fang Y, Ye J. Determination of active ingredients of Rhododendron dauricum L by capillary electrophoresis with electrochemical detection. J Chromatogr A 2002; 943: 153-7. (Pubitemid 34075310)
18. Peng YY, Liu FH, Ye JN. Determination of bioactive flavonoids in Rhododendron dauricum L by capillary electrophoresis with electrochemical detection. Chromatographia 2004; 60: 597-602. (Pubitemid 40022393)
19. Cao Y, Chu Q, Ye J. Chromatographic and electrophoretic methods for pharmaceutically active compounds in Rhododendron dauricum. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 812: 231-40. (Pubitemid 39535414)
20. Rodriguez A, Fortuno A, Gomez-Ambrosi J, Zalba G, Diez J, Fruhbeck G. The inhibitory effect of leptin on angiotensin II-induced vasoconstriction in vascular smooth muscle cells is mediated via a nitric oxidedependent mechanism. Endocrinology 2007; 148: 324-31. (Pubitemid 46021465)
21. Sasu S, LaVerda D, Qureshi N, Golenbock DT, Beasley D. Chlamydia pneumoniae and chlamydial heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation. Circ Res 2001; 89: 244-50. (Pubitemid 34132682)
22. Pizarro JG, Yeste-Velasco M, Esparza JL, Verdaguer E, Pallas M, Camins A, et al. The antiproliferative activity of melatonin in B65 rat dopaminergic neuroblastoma cells is related to the downregulation of cell cycle-related genes. J Pineal Res 2008; 45: 8-16. (Pubitemid 351986256)
23. Watanabe T, Akishita M, Nakaoka T, Kozaki K, Miyahara Y, He H, et al. Estrogen receptor β mediates the inhibitory effect of estradiol on vascular smooth muscle cell proliferation. Cardiovasc Res 2003; 59: 734-44. (Pubitemid 38368690)
24. -ΔΔCT method. Methods 2001; 25: 402-8. (Pubitemid 34164012)
25. Nelson PR, Yamamura S, Mureebe L, Itoh H, Kent KC. Smooth muscle cell migration and proliferation are mediated by distinct phases of activation of the intracellular messenger mitogen-activated protein kinase. J Vasc Surg 1998; 27: 117-25. (Pubitemid 28081167)
26. Yoon BK, Oh WJ, Kessel B, Roh CR, Choi D, Lee JH, et al. 17β-Estradiol inhibits proliferation of cultured vascular smooth muscle cells induced by lysophosphatidylcholine via a nongenomic antioxidant mechanism. Menopause 2001; 8: 58-64. (Pubitemid 32066581)
27. Geraldes P, Sirois MG, Tanguay JF. Specific contribution of estrogen receptors on mitogen-activated protein kinase pathways and vascular cell activation. Circ Res 2003; 93: 399-405. (Pubitemid 37100004)
28. Wei GL, Krasinski K, Kearney M, Isner JM, Walsh K, Andres V. Temporally and spatially coordinated expression of cell cycle regulatory factors after angioplasty. Circ Res 1997; 80: 418-26. (Pubitemid 27093357)
29. Adam RM, Borer JG, Williams J, Eastham JA, Loughlin KR, Freeman MR. Amphiregulin is coordinately expressed with heparin-binding epidermal growth factor-like growth factor in the interstitial smooth muscle of the human prostate. Endocrinology 1999; 140: 5866-75. (Pubitemid 30645375)
30. Iafrati MD, Karas RH, Aronovitz M, Kim S, Sullivan TR Jr, Lubahn DB, et al. Estrogen inhibits the vascular injury response in estrogen receptor a-deficient mice. Nat Med 1997; 3: 545-8. (Pubitemid 27198653)
31. Karas RH, Hodgin JB, Kwoun M, Krege JH, Aronovitz M, Mackey W, et al. Estrogen inhibits the vascular injury response in estrogen receptor β-deficient female mice. Proc Natl Acad Sci U S A 1999; 96: 15133-6. (Pubitemid 30019777)
32. Lindner V, Kim SK, Karas RH, Kuiper GG, Gustafsson JA, Mendelsohn ME. Increased expression of estrogen receptor-β mRNA in male blood vessels after vascular injury. Circ Res 1998; 83: 224-9. (Pubitemid 28354468)
33. Crisafulli A, Altavilla D, Marini H, Bitto A, Cucinotta D, Frisina N, et al. Effects of the phytoestrogen genistein on cardiovascular risk factors in postmenopausal women. Menopause 2005; 12: 186-92. (Pubitemid 40464287)
34. Goodman-Gruen D, Kritz-Silverstein D. Usual dietary isoflavone intake is associated with cardiovascular disease risk factors in postmenopausal women. J Nutr 2001; 131: 1202-6. (Pubitemid 32275100)